News
BITRF
0.0020
NaN%
--
Weekly Report: what happened at BITRF last week (0803-0807)?
Weekly Report · 1d ago
Weekly Report: what happened at BITRF last week (0727-0731)?
Weekly Report · 08/03 09:19
Weekly Report: what happened at BITRF last week (0720-0724)?
Weekly Report · 07/27 09:20
Weekly Report: what happened at BITRF last week (0713-0717)?
Weekly Report · 07/20 09:19
Biotron Updates Market on Directors’ Shareholding Changes
TipRanks · 07/15 06:57
Weekly Report: what happened at BITRF last week (0706-0710)?
Weekly Report · 07/13 09:19
Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway
TipRanks · 07/13 01:32
Weekly Report: what happened at BITRF last week (0629-0703)?
Weekly Report · 07/06 09:21
Weekly Report: what happened at BITRF last week (0622-0626)?
Weekly Report · 06/29 09:19
Weekly Report: what happened at BITRF last week (0615-0619)?
Weekly Report · 06/22 09:22
Biotron Lists Additional Ordinary Shares Following Option Conversions
TipRanks · 06/17 03:07
Weekly Report: what happened at BITRF last week (0608-0612)?
Weekly Report · 06/15 09:22
Weekly Report: what happened at BITRF last week (0601-0605)?
Weekly Report · 06/08 09:21
Biotron Secures R&D Tax Rebate to Support Antiviral Drug Development
TipRanks · 06/03 23:43
Weekly Report: what happened at BITRF last week (0525-0529)?
Weekly Report · 06/01 09:22
Weekly Report: what happened at BITRF last week (0518-0522)?
Weekly Report · 05/25 09:23
Weekly Report: what happened at BITRF last week (0511-0515)?
Weekly Report · 05/18 09:23
Weekly Report: what happened at BITRF last week (0504-0508)?
Weekly Report · 05/11 09:22
Weekly Report: what happened at BITRF last week (0427-0501)?
Weekly Report · 05/04 09:21
Biotron Advances SedRx Anaesthetic Program and Expands Hepatitis Portfolio
TipRanks · 04/29 00:47
More
Webull provides a variety of real-time BITRF stock news. You can receive the latest news about Biotron through multiple platforms. This information may help you make smarter investment decisions.
About BITRF
Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in developing and commercializing a novel small molecule approach that has the potential to treat several serious viral diseases. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins, including hepatitis C, HIV-1, Dengue, Zika, Influenza, and Respiratory Syncytial Virus (RSV). The Company has developed a library of over 350 compounds with potential activity against a range of viral diseases. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. The Company also owns SedRx, which is a general anesthetic containing alfaxalone.